Cancer Resources
Featured Centers
- Eating Out? Cut Calories, Heartburn
- 5 Good Ways to Save Money on Medicine
- 8 Ways to Treat Your Allergies
|
|
Medical Editor: John P. Cunha, DO, FACOEP
Tarceva (erlotinib) is used in the treatment of non-small cell lung cancer (NSCLC) or pancreatic cancer. It is a cancer chemotherapy medication. Common side effects include nausea, vomiting, loss of appetite, mouth sores, dry skin, or eye irritation.
The recommended daily dose of Tarceva for NSCLC is 150 mg taken on an empty stomach at least one hour before or two hours after the ingestion of food. The recommended daily dose of Tarceva for pancreatic cancer is 100 mg taken on an empty stomach at least one hour before or two hours after the ingestion of food, in combination with gemcitabine. For both conditions, treatment should continue until disease progression or unacceptable toxicity occurs. Tarceva may interact with HIV/AIDS medications, rifamycins, clarithromycin, nefazodone, telithromycin, troleandomycin, carbamazepine, phenobarbital, phenytoin, antifungal medications, or St. John's Wort. Tell your doctor all medications you are taking. Tarceva is not recommended for use during pregnancy. It may cause harm to a fetus or a miscarriage. Women of childbearing age should use reliable form(s) of birth control during treatment and for at least 2 weeks following the end of treatment with this drug. It is not known whether this drug passes into breast milk. Breast-feeding while using this drug is not recommended.
Our Tarceva (erlotinib) Drug Center provides a comprehensive view of available drug information as well as related drugs, user reviews, supplements, and diseases and conditions articles.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
TARCEVA (erlotinib) monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy [see Clinical Studies].
TARCEVA (erlotinib) monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen [see Clinical Studies].
Results from two, ...
Read the complete drug monograph for Tarceva »
Drug Description - Indications & Dosage - Side Effects & Drug Interactions - Warnings & Precautions - Contraindications - Medication Guide and More
What is Patient information?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
If you experience any of the following serious side effects from erlotinib, contact your doctor immediately:
Other, less serious side effects may be more likely to occur. Continue taking erlotinib and ta...
Read the complete patient information for Tarceva »
Possible Side Effects - Images - What Is - How Should I Take It - What If I Miss a Dose - What Should I Avoid and More
What is Consumer information?
A concise overview of the drug for the patient or caregiver from First DataBank.
HOW TO USE: Take this medication by mouth on an empty stomach, at least 1 hour before or 2 hours after a meal, usually once daily, or as directed by your doctor. Do not take erlotinib within 2 hours of taking an antacid (liquid or tablets). Doing so can prevent the absorption of the medication.
Acid-lowering medications for indigestion, heartburn, or ulcers (such as prescription or over-th...
Read the complete consumer information for Tarceva »
Warnings - Uses - How to Use - Side Effects - Precautions - Drug Interactions and More
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.